Supplementary tables:

Supplementary Table 1: Correlation between key clinical parameters and histopathologic findings in idiopathic membranous nephropathy

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | univariate analysis | | multivariate analysis | |
|  | odds ratio (95% CI) | P – value | odds ratio (95% CI) | P - value |
| eGFR<60 ml/min  % global sclerosis  % segmental sclerosis  % global/segmental sclerosis  interstitial inflammation  tubular atrophy/interstitial fibrosis  arteriosclerosis  % foot process effacement  stage of disease | 1.04 (1.01-1.07)  1.05 (1.01-1.10)  1.04 (1.02-1.06)  2.92 (1.71-4.98)  4.91 (2.61-9.22)  2.34 (1.44-3.80)  1.05 (0.98-1.13)  2.99 (1.55-5.77) | 0.003  0.02  <0.001  <0.001  <0.001  0.001  0.1  0.001 | 1.04 (0.96-1.12)  1.01 (0.95-1.09)  excluded  0.61 (0.19-1.98)  5.35 (1.70-16.89)  1.28 (0.58-2.84)  1.11 (0.96-1.28)  4.242 (0.92-19.60) | 0.43  0.7  0.4  0.004  0.60.2  0.06 |
| serum albumin < 2.0g/dL  % global sclerosis  % segmental sclerosis  % global/segmental sclerosis  interstitial inflammation  tubular atrophy/interstitial fibrosis  arteriosclerosis  % foot process effacement  stage of disease | 0.95 (0.89-1.01)  1.01 (0.97-1.05)  0.98 (0.95-1.01)  1.31 (0.77-2.21)  0.67 (0.42-1.08)  0.74 (0.48-1.15)  1.11 (1.00-1.23)  0.50 (0.23-1.10) | 0.09  0.7  0.2  0.3  0.1  0.2  0.05  0.08 | 0.97 (0.89-1.05)  1.02 (0.96-1.08)  excluded  3.82 (1.42-10.26)  0.65 (0.26-1.61)  0.62 (0.33-1.17)  1.17 (1.00-1.37)  0.19 (0.04-0.91) | 0.4  0.6  0.008  0.3  0.1  0.06  0.04 |
| proteinuria >3 g  % global sclerosis  % segmental sclerosis  % global/segmental sclerosis  interstitial inflammation  tubular atrophy/interstitial fibrosis  arteriosclerosis  % foot process effacement  stage of disease | 1.01 (0.98-1.04)  1 (0.95-1.05)  1 (0.98-1.03)  1.06 (0.59-1.91)  1.57 (0.92-2.70)  1.18 (0.72-1.94)  1.02 (0.98-1.06)  0.75 (0.35-1060) | 0.7  0.8  0.8  0.8  0.1  0.5  0.3  0.5 | 0.96 (0.90-1.03)  1.01 (0.95-1.07)  excluded  0.58 (0.14-1.42)  3.11 (1.20-8.06)  0.92 (0.49-1.73)  1.03 (0.98-1.09)  0.44 (0.15-1.30) | 0.2  0.7  0.2  0.02  0.8  0.2  0.1 |
| proteinuria >10 g  % global sclerosis  % segmental sclerosis  % global/segmental sclerosis  interstitial inflammation  tubular atrophy/interstitial fibrosis  arteriosclerosis  % foot process effacement  stage of disease | 1 (0.98-1.02)  1.03 (0.99-1.07)  1 (0.99-1.02)  1.74 (1.10-2.75)  1.21 (0.86-1.62)  1.13 (0.78-1.62)  1.04 (0.99-1.10)  1.06 (0.61-1.84) | 0.75  0.2  0.9  0.019  0.279  0.52  0.13  0.842 | 0.97 (0.92-1.02)  1.02 (0.97-1.08)  excluded  1.58 (0.79-3.18)  1.22 (0.64-2.13)  1.02 (0.63-1.65)  1.04 (0.97-1.11)  1.05 (0.42-2.62) | 0.2  0.4  0.2  0.5  0.9  0.3  0.9 |
| Hypertension  % global sclerosis  % segmental sclerosis  % global/segmental sclerosis  interstitial inflammation  tubular atrophy/interstitial fibrosis  arteriosclerosis  % foot process effacement  stage of disease | 1.05 (1.01-1.09)  1.01 (0.97-1.05)  1.03 (1.00-1.05)  1.35 (0.86-2.13)  1.18 (1.19-2.69)  1.15 (0.80-1.66)  1.03 (0.99-1.06)  1.93 (1.04-3.58) | 0.028  0.779  0.037  0.193  0.006  0.442  0.162  0.037 | excluded  excluded  1.01 (0.99-1.04)  excluded  1.58 (0.92-2.73)  0.92 (0.59-1.43)  excluded  1.71 (0.79-3.71) | 0.3  0.1  0.7  0.2 |
| Smoking  % global sclerosis  % segmental sclerosis  % global/segmental sclerosis  interstitial inflammation  tubular atrophy/interstitial fibrosis  arteriosclerosis  % foot process effacement  stage of disease | 1.02 (0.99-1.04)  1.01 (0.97-1.05)  1.01 (0.99-1.03)  1.46 (0.85-2.52)  1.92 (1.20-3.08)  1.94 (1.20-3.15)  1.02 (0.97-1.06)  0.91 (0.47-1.76) | 0.193  0.632  0.178  0.17  0.007  0.007  0.472  0.782 | 1.07 (0.98-1.17)  1 (0.94-1.06)  excluded  1.53 (0.61-3.83)  1.77 (0.77-4.03)  1.8 (0.97-3.32)  1.02 (0.96-1.08)  0.76 (0.25-2.37) | 0.1  1.0  0.4  0.2  0.06  0.6  0.8 |

\* variables were excluded based on conditional entry of the variable by the likelihood ratio

Supplementary Table 2: Treatment utilization in the study population

|  |  |  |
| --- | --- | --- |
| **treatment** | N | % |
| ACEi/ARBs | 108 | 84 |
| Statin | 90 | 78 |
| immunosuppressants  steroids  cyclophosphamide  mycophenolate mofetil  cyclosporine  tacrolimus  rituximab | 98  79  32  49  62  10  16 | 74  60  24  37  47  8  12 |